Hepatitis B affects nearly 300 million people worldwide and is the leading cause of liver cancer. Existing antivirals control the virus and prevent liver damage but rarely produce a cure. Research is now intensely focused on functional cures — driving the virus to undetectable levels without lifelong medication.
What's actually going on in research
Trials are testing siRNA drugs that silence viral proteins, antisense oligonucleotides, capsid inhibitors, therapeutic vaccines, and combinations aimed at functional cure. Researchers are also studying treatment in pregnancy, hepatitis B and D coinfection, and screening to find the millions of people unaware they are infected.
Functional cure
Combinations of siRNA drugs, capsid inhibitors, and therapeutic vaccines are aiming to drive hepatitis B into long-term remission without lifelong medication. Late-stage trials are underway.
New drug classes
siRNA drugs silence viral proteins, while capsid inhibitors block virus assembly. Each works differently from current antivirals and may be most powerful in combination.
Hepatitis D coinfection
Bulevirtide, a new drug for hepatitis B and D coinfection, is approved in Europe and being studied in the US. It is the first targeted treatment for the most severe form of viral hepatitis.
What to know before you search
Eligibility often depends on viral load, liver function, presence of liver damage, hepatitis B surface antigen levels, and hepatitis D coinfection.
What types of trials are currently open
- Treatment trials — Testing new antivirals, siRNA drugs, and combinations aimed at controlling or curing hepatitis B.
- Functional cure trials — Testing combinations of new drugs to drive hepatitis B into long-term remission off medication.
- Vaccine trials — Testing therapeutic vaccines designed to help the immune system control hepatitis B.
- Hepatitis D trials — Testing treatments for hepatitis B and D coinfection.
- Observational studies — Following people with hepatitis B to understand liver disease, cancer risk, and treatment response.
Recently added Hepatitis B trials
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.
A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
The objectives of this study are as follows: To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care settings To evaluate the usability of the TruPlex test through: Structured usability assessments, via a questionnaire, completed by trained operators in point-of-care settings. To assess user interpretation accuracy through a contrived result interpretation questionnaire, where intended users evaluate a set of pre-defined test results (e.g., strong/weak positives, negatives, invalids). To monitor test system reliability, including invalid rates.
Find Hepatitis B trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.